Therafirst Medical Center
Fort Lauderdale, Florida, 33308, United States
NCT Number: NCT06368453
The objective of this study is to evaluate the performance, usability, and result interpretation of the INSTI® HIV Self-Test (referred to INSTI® HIV ST) in the intended use population across the United States (US). The INSTI® HIV Self-Test is a single use in vitro test that is used as a self-test for the detection of antibodies to HIV-1 and HIV-2 in human fingerstick blood. This study is designed to evaluate INSTI® HIV ST performance in the hands of non-professionals and untrained lay users who are inexperienced in HIV blood-based self-testing.
The study aims to:
To evaluate the clinical performance (i.e., diagnostic sensitivity and specificity) of the INSTI® HIV Self-Test in a lay user population.
To assess the user's comprehension of the INSTI® HIV ST results (e.g., interpreting positive, negative, and invalid results).
To evaluate the usability of the INSTI® HIV ST and understand users' experience in performing the test.
Looking for future studies?
Notify Me18 year and older
All sexes
Interventional
Not applicable
Fort Lauderdale, Florida, 33308, United States
The objective of this study is to evaluate the performance, usability, and result interpretation of the INSTI® HIV Self-Test (referred to INSTI® HIV ST) in the intended user population across the United States (US). This study is designed to evaluate INSTI® HIV ST performance in the hands of non-professionals and untrained lay users who are inexperienced in HIV self-testing.
The study aims to:
To evaluate the clinical performance (i.e., diagnostic sensitivity and specificity) of the INSTI® HIV ST in a lay user population.
To assess the user's comprehension of the INSTI® HIV ST results (e.g., interpreting positive, negative, and invalid results).
To evaluate the usability of the INSTI® HIV ST and understand users' experience in performing the test.
Subjects will be consecutively enrolled from the 'general' population (i.e., "all comers" group of previously undiagnosed HIV individuals) until a minimum of 27 HIV positive and 1000-1700 HIV negatives are obtained. Subjects will be lay users recruited at multiple sites across the US. This study is to determine if lay users, unassisted, can perform the INSTI® HIV ST correctly and without significant risk of incorrect results. The study will help to determine if the INSTI® HIV ST instructions are easy to understand for the US public. The overall study processes include a performance evaluation, where subjects will perform the INSTI® HIV ST, a mock results interpretation study to assess the user's comprehension of the INSTI® HIV ST results and usability evaluation to understand users experience with the INSTI® HIV ST. Only a subset of the enrolled subjects (500 subjects) will participate in the mock results interpretation study and usability evaluation.
For the performance evaluation, subjects will perform the INSTI® HIV ST without any intervention from an observer. Following the subjects self-testing, an operator will collect an additional fingerstick sample to perform a comparator test. The positive and negative percent agreement (i.e., PPA and NPA) between the INSTI® HIV ST result and comparator will be calculated. In the event of discrepant results between the INSTI® HIV ST and comparator test, an additional venous blood sample will be collected from the subject for discrepancy testing.
A subset of the enrolled subjects will then participate in the mock results interpretation study and usability evaluation. For the mock study, the subjects will be presented with 5 mock INSTI® HIV ST devices with different results, and the subject's interpretation of each device will be recorded. The percentage of subjects who interpreted the mock results correctly for each result type will be calculated.
For the INSTI® HIV ST usability evaluation, the subjects will be presented with a questionnaire. The overall results of the questionnaire will be used to determine the percentage of subjects who found the INSTI® HIV ST easy to use.
Healthy volunteers accepted: Yes
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Each participant will be provided with the INSTI® HIV Self-Test and asked to conduct self testing. The operator will observe the participant and record the subject's interpretation of the results. Subjects will perform the test without intervention from the operator.
The operator will then perform the comparator test and collect a fingerstick blood sample. In the event of a discrepant result between the INSTI® HIV ST and comparator test, an additional venous blood sample will be collected from the subject and sent for discrepancy testing.
Time frame: 12 Months
The positive percent agreement (PPA) and negative percent agreement (NPA) between the INSTI® HIV ST and comparator test will be determined. The two-sided confidence interval for the PPA and NPA will be determined.
The percentage of assays with INSTI® HIV ST invalid results will be determined.
Time frame: 12 Months
The percentage of subjects who interpreted the INSTI® HIV ST mock results correctly for each result type will be determined.
The usability questionnaire will be used to determine the following:
The percentage of subjects who found the INSTI® HIV ST easy to use. The percentage of subjects who found the INSTI® HIV ST product information easy to use.
The percentage of subjects willing to use the INSTI® HIV ST again The percentage of subjects willing to recommend the INSTI® HIV ST
bioLytical Laboratories
Industry
A Study to Evaluate the Performance, Usability, and Result Interpretation of INSTI® HIV Self-Test When Performed by Observed Intended Users in the US
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT07061912
Human Immunodeficiency Virus I Infection, Human Immunodeficiency Virus II Infection
Richmond, British Columbia, Canada
View Trial DetailsNCT06253533
Acquired Immunodeficiency Syndrome, Blood-Borne Infections
Shenzhen, Guangdong, China
View Trial DetailsNCT05031819
Acquired Immunodeficiency Syndrome, Blood Pressure
Uyo, Akwa Ibom State, Nigeria
View Trial DetailsNCT05261191
Acquired Immunodeficiency Syndrome, Blood-Borne Infections
New York, United States
View Trial Details